TY - JOUR
AU - Riggioni, Carmen
AU - Comberiati, Pasquale
AU - Giovannini, Mattia
AU - Agache, Ioana
AU - Akdis, Mübeccel 
AU - Alves‐Correia, Magna
AU - Antó, Josep M.
AU - Arcolaci, Alessandra
AU - Kursat Azkur, Ahmet
AU - Azkur, Dilek
AU - Beken, Burcin
AU - Boccabella, Cristina
AU - Bousquet, Jean
AU - Breiteneder, Heimo
AU - Carvalho, Daniela
AU - De Las Vecillas, Leticia
AU - Diamant, Zuzana
AU - Eguiluz‐Gracia, Ibon
AU - Eiwegger, Thomas
AU - Eyerich, Stefanie
AU - Fokkens, Wytske J.
AU - Gao, Yadong
AU - Hannachi, Farah
AU - Johnston, Sebastian L.
AU - Jutel, Marek
AU - Karavelia, Aspasia
AU - Klimek, Ludger
AU - Moya, Beatriz
AU - Nadeau, Kari C.
AU - O'Hehir, Robyn E.
AU - O'Mahony, Liam
AU - Pfaar, Oliver
AU - Sanak, Marek
AU - Schwarze, Jürgen
AU - Sokolowska, Milena
AU - Torres, María José
AU - Van De Veen, Willem
AU - Van Zelm, Menno C.
AU - Wang, De Yun
AU - Zhang, Luo
AU - Jiménez‐Saiz, Rodrigo
AU - Akdis, Cezmi A.
PY - 2020
DA - June
TI - A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
JO - Allergy
DO - https://doi.org/10.1111/all.14449
AB - In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID‐19). This disease, caused by the severe acute respiratory syndrome‐related coronavirus 2 (SARS‐CoV‐2), has developed into a pandemic. To date it has resulted in ~6.5 million confirmed cases and caused almost 400,000 related deaths worldwide. Unequivocally, the COVID‐19 pandemic is the gravest health and socio‐economic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence‐based medical advice on SARS‐CoV‐2 and COVID‐19. Although the majority of the patients show a very mild, self‐limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID‐19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, thrombo‐embolic complications and multiorgan failure. The epidemiologic features of COVID‐19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID‐19‐related topics should be based on more coordinated high‐quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS‐CoV‐2, COVID‐19 and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development and epidemiology. Over 140 questions were answered by experts in the field providing a comprehensive and practical overview of COVID‐19 and allergic disease.
PB - Wiley
UR - https://www.research.ed.ac.uk/en/publications/104b1f0f-6b76-4982-89c8-850dbe37451e
KW - Coronavirus (COVID-19)
ER